 |
New, State-of-the-art Testing for EhrlichiaFebruary 5, 2001, Palo Alto, CA — IGeneX, Inc. today announced the availability of two newly developed PCR tests for Ehrlichiosis. IGeneX, Inc. becomes one of the only laboratories in the United States to commercially offer PCR for both Human Granulocytic and Monocytic Ehrlichiosis (HGE and HME respectively). These PCR tests, combined with the IFA antibody tests, become a comprehensive and cost-effective TICK-BORNE DISEASE testing panel to assist in the diagnosis of Human Granulocytic Ehrlichiosis (HGE) and Human Monocytic Ehrlichiosis (HME). These diseases are caused by rickettsial bacteria, which are intracellular parasites for granulocytes and monocytes respectively. Most patients have a history of tick bite, accompanied by a mild to an acute infection with fever, myalgias and malaise. In the fulminate stage, nausea, vomiting and severe headache may be present. Laboratory findings include increased WBC's and antibodies to the agent responsible for HGE and/or HME. In cases of acute or persistent disease, findings include the presence of the organisms' DNA by the Polymerase chain reaction (PCR). These new panels provide a cost-effective approach to both IFA and PCR testing for both organisms. In addition to the new Ehrlichia panel, IGeneX, Inc. has created new comprehensive and cost-effective panels for Babesia and Lyme Disease, as well as a PCR-based TICK TESTING panel for Babesia, Lyme, and Ehrlichia. IGeneX, Inc. can be reached at 800 832 3200. IGeneX,
Inc. |